The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Mcclure Natalie since 2014.
The trader's CIK number is 1604572.
At the time of the last reporting, Mcclure Natalie was the SVP, Product Development of Adamas Pharmaceuticals Inc. (stock ticker symbol ADMS).
Also see all insider trading activities at Adamas Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2016 | ADMS | 0 | $0 | 36,000 | $666,000 | 36,000 | $43,560 |
| 2015 | ADMS | 0 | $0 | 12,000 | $211,240 | 12,000 | $21,060 |
| 2014 | ADMS | 0 | $0 | 22,000 | $318,028 | 22,000 | $38,610 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2016-04-18 | ADMS | Option Ex | 36,000 | 1.21 | 43,560 |
| 2016-04-18 | ADMS | Sale | 36,000 | 18.50 | 666,000 |
| 2015-06-05 | ADMS | Option Ex | 2,000 | 1.75 | 3,510 |
| 2015-06-05 | ADMS | Sale | 2,000 | 18.95 | 37,900 |
| 2015-05-05 | ADMS | Sale | 2,000 | 17.62 | 35,240 |
| 2015-05-05 | ADMS | Option Ex | 2,000 | 1.75 | 3,510 |
| 2015-04-06 | ADMS | Option Ex | 2,000 | 1.75 | 3,510 |
| 2015-04-06 | ADMS | Sale | 2,000 | 17.44 | 34,880 |
| 2015-03-05 | ADMS | Option Ex | 2,000 | 1.75 | 3,510 |
| 2015-03-05 | ADMS | Sale | 2,000 | 17.15 | 34,300 |
| 2015-02-05 | ADMS | Option Ex | 2,000 | 1.75 | 3,510 |
| 2015-02-05 | ADMS | Sale | 2,000 | 16.87 | 33,740 |
| 2015-01-05 | ADMS | Sale | 2,000 | 17.59 | 35,180 |
| 2015-01-05 | ADMS | Option Ex | 2,000 | 1.75 | 3,510 |
| 2014-12-05 | ADMS | Option Ex | 2,000 | 1.75 | 3,510 |
| 2014-12-05 | ADMS | Sale | 2,000 | 14.01 | 28,028 |
| 2014-12-01 | ADMS | Option Ex | 20,000 | 1.75 | 35,100 |
| 2014-12-01 | ADMS | Sale | 20,000 | 14.50 | 290,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mcclure Natalie (SVP, Product Development of Adamas Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.